Table 2.
Characteristics of the studies included in this meta-analysis.
| Author | Na/Nb | Course | Experimental | Control | Outcome |
|---|---|---|---|---|---|
| Acute pelvic inflammatory | |||||
| CCJ (2018) [27] | 35/35 | 15 | FKQJP + C | Penicillin | ①③ |
| YML (2013) [28] | 24/23 | 12 | FKQJP + C | Penicillin | ① |
| ZJ (2017) [29] | 48/48 | 15 | FKQJP + C | Penicillin | ①③ |
| DY (2014) [30] | 68/68 | 10∼15 | FKQJP + C | Penicillin | ①②③④ |
| SL (2015) [31] | 50/50 | 10 | FKQJP + C | Penicillin | ①②④ |
| TSQ (2019) [32] | 50/50 | 10 | FKQJP + C | Penicillin | ① |
| XQX (2014) [33] | 39/39 | 15 | FKQJP + C | Penicillin + metronidazole | ①②③ |
| YFY (2013) [34] | 67/68 | 10∼15 | FKQJP + C | Penicillin + metronidazole | ①③ |
| RS (2012) [35] | 36/36 | 10 | FKQJP + C | Penicillin + metronidazole | ①② |
| SFM (2015) [36] | 66/66 | 10 | FKQJP + C | Penicillin + metronidazole | ①② |
| ZY (2013) [37] | 43/43 | 10 | FKQJP + C | Penicillin + metronidazole | ①④ |
| FXH (2018) [38] | 39/39 | 14 | FKQJP + C | Penicillin + metronidazole | ①②③④ |
| SYQ (2015) [39] | 110/110 | 15 | FKQJP + C | Penicillin + metronidazole | ①③ |
| ZHY (2012) [40] | 60/60 | 10 | FKQJP + C | Roxithromycin | ①② |
| ZYZ (2012) [41] | 30/30 | 12 | FKQJP + C | Roxithromycin | ①② |
| YCQ (2017) [42] | 60/60 | 7∼14 | FKQJP + C | Moxifloxacin | ①② |
| LWR (2013) [43] | 43/43 | 10 | FKQJP + C | Levofloxacin hydrochloride | ①③④ |
| WGJ (2011) [44] | 50/50 | 14 | FKQJP + C | Ceftriaxone + tinidazole | ①② |
| HRM (2013) [45] | 60/60 | 7∼15 | FKQJP + C | Ceftriaxone + tinidazole | ①② |
| GSY (2012) [46] | 30/30 | 10 | FKQJP + C | Levofloxacin lactate + metronidazole | ①② |
| ZYH (2016) [47] | 40/40 | 7∼14 | FKQJP + C | Gatifloxacin + metronidazole | ①② |
| ZNN (2012) [48] | 30/30 | 12 | FKQJP + C | Metronidazole | ①② |
| LJ (2014) [49] | 36/36 | 14 | FKQJP + C | Metronidazole | ①④ |
|
| |||||
| Chronic pelvic inflammatory | |||||
| LJX2 (2014) [50] | 40/40 | 42 | FKQJP | β-Lactam + nitroimidazole | ① |
| XZJ (2007) [51] | 102/102 | 45/21 | FKQJP | β-Lactam + nitroimidazole | ① |
| CXC (2019) [52] | 64/64 | 21 | FKQJP + C | β-Lactam | ①④ |
| DJL (2014) [53] | 62/62 | 21 | FKQJP + C | β-Lactam | ①② |
| PGZ (2016) [54] | 40/40 | 14 | FKQJP + C | β -Lactam | ①②③ |
| SXL (2015) [55] | 32/32 | 21 | FKQJP + C | β-Lactam | ①③ |
| WQF (2013) [56] | 35/35 | 20 | FKQJP + C | β-Lactam | ① |
| ZXJ (2015) [57] | 30/30 | 14 | FKQJP + C | β-Lactam | ①② |
| ZMY (2017) [58] | 50/50 | 14 | FKQJP + C | β-Lactam | ①② |
| LJX1 (2014) [50] | 40/40 | 42 | FKQJP + C | β-Lactam + nitroimidazole | ① |
| LXX (2019) [59] | 43/43 | 15 | FKQJP + C | β-Lactam + nitroimidazole | ① |
| LH (2019) [60] | 52/52 | 14 | FKQJP + C | β-Lactam + nitroimidazole | ①② |
| PJQ (2019) [61] | 75/75 | 15 | FKQJP + C | β-Lactam + nitroimidazole | ① |
| SWA (2014) [62] | 36/36 | 28 | FKQJP + C | β-Lactam + nitroimidazole | ① |
| SQB2 (2012) [63] | 50/50 | 28 | FKQJP + C | β-Lactam + nitroimidazole | ①② |
| ZY (2014) [64] | 54/54 | 28 | FKQJP + C | β-Lactam + nitroimidazole | ①② |
| SQB1 (2012) [63] | 50/50 | 28 | FKQJP+β-lactam + nitroimidazole | FKQJP | ①② |
| SPF (2015) [65] | 75/75 | 14 | FKQJP+β-lactam + nitroimidazole | FKQJP | ①② |
| CF (2018) [66] | 60/60 | 42 | FKQJP + C | Macrolide | ①② |
| DLL (2017) [67] | 81/81 | 42 | FKQJP + C | Macrolide | ①② |
| FJY (2010) [68] | 63/63 | 15 | FKQJP + C | Macrolide | ①② |
| FP (2013) [69] | 62/62 | 14 | FKQJP + C | Macrolide | ① |
| KY (2018) [70] | 100/86 | 14 | FKQJP + C | Macrolide | ①③ |
| LMY (2016) [71] | 50/50 | 14 | FKQJP + C | Macrolide | ① |
| LYK (2016) [72] | 30/30 | 15 | FKQJP + C | Macrolide | ①② |
| LongH (2011) [73] | 90/90 | 28 | FKQJP + C | Macrolide | ① |
| RDQ (2019) [74] | 40/40 | 21 | FKQJP + C | Macrolide | ① |
| ShaoXL (2012) [75] | 87/86 | 15 | FKQJP + C | Macrolide | ① |
| TXG (2015) [76] | 90/90 | 15 | FKQJP + C | Macrolide | ①② |
| WJP (2013) [77] | 52/48 | 51 | FKQJP + C | Macrolide | ① |
| YM (2017) [78] | 50/50 | 51 | FKQJP + C | Macrolide | ① |
| YQ (2014) [79] | 67/67 | 15 | FKQJP + C | Macrolide | ①② |
| ZYL (2017) [80] | 40/40 | 20 | FKQJP + C | Macrolide | ①② |
| DLH (2019) [81] | 45/45 | 30 | FKQJP + C | Quinolone | ① |
| HJY (2019) [82] | 31/31 | 30 | FKQJP + C | Quinolone | ①④ |
| LJ (2019) [83] | 22/22 | 14 | FKQJP + C | Quinolone | ①② |
| SJL (2016) [84] | 53/53 | 30 | FKQJP + C | Quinolone | ① |
| WJ (2018) [85] | 40/40 | 14 | FKQJP + C | Quinolone | ① |
| ZL (2015) [86] | 40/40 | 21 | FKQJP + C | Quinolone | ① |
| ZT (2018) [87] | 160/160 | 21 | FKQJP + C | Quinolone | ①④ |
| ZhaoJ (2017) [88] | 55/55 | 28 | FKQJP + C | Quinolone | ①④ |
| ZengJ (2016) [89] | 40/40 | 14 | FKQJP + C | Quinolone + nitroimidazole | ①② |
| CXF (2018) [90] | 58/58 | 42 | FKQJP + C | Quinolone + nitroimidazole | ①③ |
| DCM (2016) [91] | 47/47 | 28 | FKQJP + C | Quinolone + nitroimidazole | ①③ |
| DQY (2015) [92] | 25/25 | 28 | FKQJP + C | Quinolone + nitroimidazole | ①② |
| HSX (2019) [93] | 65/65 | 42 | FKQJP + C | Quinolone + nitroimidazole | ①② |
| HHJ (2019) [94] | 60/60 | 28 | FKQJP + C | Quinolone + nitroimidazole | ① |
| HHM (2019) [95] | 63/63 | 28 | FKQJP + C | Quinolone + nitroimidazole | ①②③④ |
| HYL (2015) [96] | 60/60 | 32 | FKQJP + C | Quinolone + nitroimidazole | ①② |
| LML (2019) [97] | 29/29 | 14 | FKQJP + C | Quinolone + nitroimidazole | ①③ |
| LHR (2013) [98] | 45/41 | 28 | FKQJP + C | Quinolone + nitroimidazole | ①②③ |
| LXL (2018) [99] | 41/41 | 14 | FKQJP + C | Quinolone + nitroimidazole | ①④ |
| LSY (2018) [100] | 587/588 | 28 | FKQJP + C | Quinolone + nitroimidazole | ①③④ |
| LYZ (2012) [101] | 35/35 | 28 | FKQJP + C | Quinolone + nitroimidazole | ①③ |
| MYQ (2019) [102] | 30/30 | 28 | FKQJP + C | Quinolone + nitroimidazole | ① |
| RC (2016) [103] | 60/60 | 14 | FKQJP + C | Quinolone + nitroimidazole | ① |
| RL (2017) [104] | 43/43 | 28 | FKQJP + C | Quinolone + nitroimidazole | ①② |
| SNY·HSY (2016) [105] | 40/40 | 20 | FKQJP + C | Quinolone + nitroimidazole | ①② |
| SQJ (2012) [106] | 30/30 | 14 | FKQJP + C | Quinolone + nitroimidazole | ①② |
| YLH (2012) [107] | 42/42 | 28 | FKQJP + C | Quinolone + nitroimidazole | ①③④ |
| WDD (2017) [108] | 35/35 | 28 | FKQJP + C | Quinolone + nitroimidazole | ① |
| WHL (2011) [109] | 90/90 | 28 | FKQJP + C | Quinolone + nitroimidazole | ①③ |
| WLY (2019) [110] | 50/50 | 30 | FKQJP + C | Quinolone + nitroimidazole | ①② |
| WSY (2011) [111] | 50/50 | 90 | FKQJP + C | Quinolone + nitroimidazole | ① |
| WY (2018) [112] | 36/36 | 28∼42 | FKQJP + C | Quinolone + nitroimidazole | ① |
| WDM (2019) [113] | 48/48 | 28 | FKQJP + C | Quinolone + nitroimidazole | ①② |
| XW (2015) [114] | 65/63 | 28 | FKQJP + C | Quinolone + nitroimidazole | ①③ |
| XRQ (2018) [115] | 37/37 | 28 | FKQJP + C | Quinolone + nitroimidazole | ①③ |
| YDM (2015) [116] | 30/30 | 28 | FKQJP + C | Quinolone + nitroimidazole | ①② |
| YXH (2016) [117] | 53/53 | 42 | FKQJP + C | Quinolone + nitroimidazole | ①② |
| ZhangJ (2017) [118] | 35/35 | 14 | FKQJP + C | Quinolone + nitroimidazole | ①② |
|
| |||||
| Endometritis | |||||
| SFF (2017) [119] | 44/44 | 45 | FKQJP + C | Cefoxitin + doxycycline | ④ |
| SCP (2019) [120] | 46/46 | 45 | FKQJP + C | Cefoxitin + doxycycline | ① |
| DYY (2019) [121] | 174/174 | 45 | FKQJP + C | Cefoxitin + doxycycline | ①③④ |
| LY (2019) [122] | 34/33 | 45 | FKQJP + C | Cefoxitin + doxycycline | ③④ |
| HHF (2017) [123] | 60/60 | 21 | FKQJP + C | Levofloxacin | ①②③④ |
| WJF (2019) [124] | 60/60 | 21 | FKQJP + C | Levofloxacin | ①③④ |
| MTX (2016) [125] | 40/40 | 14/42 | FKQJP + metronidazole | Metronidazole + medroxyprogesterone | ①③⑤ |
| SXW (2018) [126] | 45/45 | 42 | FKQJP + metronidazole | Metronidazole + medroxyprogesterone | ①②④ |
| ZHH (2018) [127] | 52/52 | 42 | FKQJP + metronidazole | Metronidazole + medroxyprogesterone | ①③⑤ |
| ZL (2019) [128] | 34/34 | 30 | FKQJP + metronidazole | Metronidazole + medroxyprogesterone | ①③④ |
| DCL (2017) [129] | 20/20 | 42 | FKQJP + metronidazole | Metronidazole + medroxyprogesterone | ① |
| DFY (2017) [130] | 80/80 | 42 | FKQJP + metronidazole | Metronidazole + medroxyprogesterone | ①③⑤ |
| GY (2015) [131] | 78/78 | 14/42 | FKQJP + metronidazole | Metronidazole + medroxyprogesterone | ①④ |
| LWP (2019) [132] | 39/39 | 30 | FKQJP + metronidazole | Metronidazole + medroxyprogesterone | ① |
| MYJ (2018) [133] | 42/42 | 42 | FKQJP + metronidazole | Metronidazole + medroxyprogesterone | ① |
| DFL (2017) [134] | 41/41 | 42 | FKQJP + metronidazole | Metronidazole + medroxyprogesterone | ①③④ |
| HXY (2018) [135] | 50/50 | 14/42 | FKQJP + metronidazole | Metronidazole + medroxyprogesterone | ①④ |
| ZQ (2019) [136] | 40/40 | 42 | FKQJP + metronidazole | Metronidazole + norethisterone | ①③④ |
| LXZ (2017) [137] | 64/64 | 14 | FKQJP + C | Metronidazole + medroxyprogesterone | ①②③ |
| CXH (2017) [138] | 30/30 | 60 | FKQJP + C | Metronidazole + medroxyprogesterone | ① |
| FCF (2016) [139] | 90/90 | 14/42 | FKQJP + C | Metronidazole + medroxyprogesterone | ①③④ |
| LBY (2019) [140] | 30/30 | 14/42 | FKQJP + C | Metronidazole + medroxyprogesterone | ①③④ |
| LSQ (2017) [141] | 45/44 | 42 | FKQJP + C | Metronidazole + medroxyprogesterone | ①②③④ |
| YL (2018) [142] | 40/40 | 14/42 | FKQJP + C | Metronidazole + medroxyprogesterone | ①④ |
| ZQ (2016) [143] | 156/156 | 14/60 | FKQJP + C | Metronidazole + medroxyprogesterone | ①④⑤ |
| ZCY (2018) [144] | 14/14 | 42 | FKQJP + C | Metronidazole + medroxyprogesterone | ①④ |
| ZGB (2017) [145] | 41/41 | 42 | FKQJP + C | Metronidazole + medroxyprogesterone | ① |
| GLJNT (2017) [146] | 90/90 | 42 | FKQJP + C | Metronidazole + norethisterone | ①③ |
| CJH (2016) [147] | 40/40 | 42 | FKQJP + C | Metronidazole + norethisterone | ①③ |
| AYGL (2018) [148] | 40/40 | 42 | FKQJP + C | Metronidazole + norethisterone | ③④ |
| SXX (2018) [149] | 70/70 | 42 | FKQJP + C | Metronidazole + norethisterone + vaginal douche | ①③④ |
| XCY (2015) [150] | 75/75 | 21 | FKQJP + C | Metronidazole + norethisterone + vaginal douche | ①③④ |
| HF (2016) [151] | 75/75 | 21 | FKQJP + C | Metronidazole + norethisterone + vaginal douche | ①④ |
Note. ①, total effective rate; ②, incidence of adverse reaction; ③, the time of clinical symptom remission/disappearance; ④, serum inflammatory factor concentration. FKQJP, Fuke Qianjin tablet; C, control group regimens.